Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) shares are jumping up close to 16% after the drug maker released top-line data from its Phase 3 study …
In a research report issued Monday, Needham analyst Alan Carr upgraded shares of Genocea Biosciences Inc (NASDAQ:GNCA), while setting a new price target of $12.00, which …
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares are on a 7% rise after the company revealed yesterday the FDA has cancelled its prior-scheduled Advisory Committee …
Genocea Biosciences Inc (NASDAQ:GNCA) shares are surging nicely ahead 8% today after the firm hosted an R&D day yesterday via a webinar providing …
Achaogen Inc (NASDAQ:AKAO) shares were shooting through the roof at 148% yesterday after the biotech firm pleasantly surprised investors with two Phase 3 …
In a research report released Friday, Needham analyst Alan Carr downgraded shares of Cempra Inc (NASDAQ:CEMP) from Buy to Hold rating, as he sees management …
In a research report issued Tuesday, Needham analyst Alan Carr reiterated a Hold rating on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), after the drug maker reported third-quarter results and …
Needham analyst Alan Carr weighs in on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) after hosting a call last week with key opinion leader (KOL) Dr.
Analysts offer insights into a volatile biotech-verse amid Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares dipping on news of a program termination and Aurinia Pharmaceuticals (NASDAQ:AUPH) soaring on …
In a research report issued Friday, Needham analyst Alan Carr reiterated a Buy rating on shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) with a price …
